Sponsors flock to new opportunities in pharma services

Companies providing services to drug-makers are particularly hot. Sales of recent assets have commanded EBITDA multiples in the mid-teens to 20x.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this